**South African National Essential Medicines List**

**Cost-Comparison Analysis**

**Name of STG ERC**

**Component: STG chapter and section**

**Generic name of health technology and relevant indication (e.g. x for treating x)**

**Date**

# EXECUTIVE SUMMARY

|  |
| --- |
| **Medicine:** **Indication:** **Research question:****Patient population:** **Level of Care:** **Prescriber level:** **Current Standard of Care/ Comparator(s):** **Methods:****Findings:**  **Recommendations:****Reviewers:** **PTC affiliation:** **Disclosures:** **Funding support:**  |

**NAMES OF REVIEWERS**

**AFFILIATION AND CONFLICT OF INTEREST**

Potential conflict of interest statement included here.

Official form should be completed and sent to EDP prior to undertaking the review:

# INTRODUCTION

Brief description of the following:

* Rationale for why this type of analysis has been selected
* Brief description of the condition, the current care pathway and treatment alternatives already available in the South African public health sector (reference Standard Treatment Guidelines and other Department of Health clinical guidelines, if relevant).
* Identify the main resource use associated with the technology under review and its comparators

# Cost-comparison assumptions

* Clinical care pathway and related resource use and costs
* Time horizon, include rationale for the choice

# Identifying and estimating resource use

Describe methods used to identify and calculate costs (see HTA Methods Guide for guidance).

* Quantity and unit cost for each resource with justification why it was chosen, with a supporting reference (and for prices, the reference year)
* Clearly described calculations or submit a document where interim calculations can be seen
* Describe any quality assurance applied to the costs and/or resource use inputs (e.g. confirmed by clinical experts)

Adapt tables below to present the acquisition, healthcare resource use, and adverse events costs of the intervention and comparator technologies.

1. **Acquisition costs of the intervention and comparator technologies**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Intervention | Source | Comparator | Source |
| Pharmaceutical formulation | *e.g. Tablet* | *SAHPRA PI* |  |  |
| Method of administration | *e.g. Oral* | *SAHPRA PI* |  |  |
| Average dose/s and dosing schedule/s | *e.g. 10mg tablet once a day* |  |  |  |
| Average daily dose | *e.g. 10mg* |  |  |  |
| Dose adjustments | *n/a* |  |  |  |
| Acquisition cost for smallest available pack size  | *e.g. R25 for 30 x 10mg tablets* | *Master Health Product List* *\** |  |  |
| Cost of one dosing unit | *e.g. R25*$÷$*30=R0.83* |  |  |  |
| Cost of treatment for one day | *R0.83* |  |  |  |
| Average length of a course of treatment | *One year (chronic treatment)* |  |  |  |
| Cost of a course of treatment  | *R300* |  |  |  |
| (Anticipated) average interval between courses of treatment | *n/a* |  |  |  |
| (Anticipated) number of repeat courses of treatment | *n/a* |  |  |  |

Table adapted from the NICE cost-comparison submission template

\* Source from the latest Master Health Product List (<http://www.health.gov.za/tenders/>), with the contract number and item number referenced for each medicine.

1. **Healthcare resource costs of the intervention and comparator technologies**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Intervention | Source and justification | Comparator | Source and justification |
| Resource 1 |  |  |  |  |
| Unit cost |  |  |  |  |
| Number of units per course of treatment |  |  |  |  |
| Total cost of Resource 1: |
| Per day |  |  |  |  |
| Per course of treatment |  |  |  |  |
| Over full time horizon |  |  |  |  |
| Resource 2 |  |  |  |  |
| Unit cost |  |  |  |  |
| Units per course of treatment |  |  |  |  |
| Total cost of Resource 2: |
| Per day |  |  |  |  |
| Per course of treatment |  |  |  |  |
| Over full time horizon |  |  |  |  |
| *Add more rows, as needed* |  |  |  |  |

 Adapted from the NICE cost-comparison submission template

1. **Adverse events resource costs of the intervention and comparator technologies**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Intervention | Source and justification | Comparator | Source and justification |
| ADVERSE EVENT 1 |  |  |  |  |
| Resource 1 |  |  |  |  |
| Unit cost |  |  |  |  |
| Number of units per course of treatment |  |  |  |  |
| Probability of patient experiencing adverse event per year |  |  |  |  |
| Total cost of Resource 1: |
| Per day |  |  |  |  |
| Per course of treatment |  |  |  |  |
| Over full time horizon |  |  |  |  |
| Resource 2 |  |  |  |  |
| Unit cost |  |  |  |  |
| Units per course of treatment |  |  |  |  |
| Probability of patient experiencing adverse event per year |  |  |  |  |
| Total cost of Resource 2: |
| Per day |  |  |  |  |
| Per course of treatment |  |  |  |  |
| Over full time horizon |  |  |  |  |
| *Add more rows, as needed* |  |  |  |  |

Adapted from the NICE cost-comparison submission template (14)

1. **Other costs or cost savings not captured elsewhere**

# Summary of total cost

Describe base-case cost-comparison analysis results.

Adapt table below for reporting

**Total costs associated with the intervention and comparator**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Intervention | Comparator | *Add more rows, if needed* |
| Acquisition costs |  |  |  |
| Health resource costs  |  |  |  |
| Adverse event costs  |  |  |  |
| Other costs  |  |  |  |
| Total costs |  |  |  |
| State the time horizon  |

# Sensitivity analysis

Report any uncertainties in costs or resource use inputs.

Outline the approach taken to sensitivity analysis and scenario analysis to explore uncertainty and provide a table with the results.

# Subgroup analysis

Report any subgroup analysis results, if relevant

# Interpretation of the cost-comparison analysis

Conclusion on the cost of intervention technology compared to comparator.

# REFERENCES

Vancouver style format